 Albuminuria
"Albuminuria" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Descriptor ID |
D000419
|
| MeSH Number(s) |
C12.777.934.734.269 C13.351.968.934.734.269 C23.888.942.750.269
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Albuminuria".
Below are MeSH descriptors whose meaning is more specific than "Albuminuria".
This graph shows the total number of publications written about "Albuminuria" by people in this website by year, and whether "Albuminuria" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 1 | 0 | 1 | | 1993 | 0 | 3 | 3 | | 1994 | 3 | 1 | 4 | | 1996 | 3 | 1 | 4 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 4 | 0 | 4 | | 2003 | 2 | 5 | 7 | | 2004 | 5 | 2 | 7 | | 2005 | 1 | 4 | 5 | | 2006 | 4 | 2 | 6 | | 2007 | 3 | 1 | 4 | | 2008 | 3 | 3 | 6 | | 2009 | 3 | 8 | 11 | | 2010 | 6 | 6 | 12 | | 2011 | 1 | 5 | 6 | | 2012 | 1 | 3 | 4 | | 2013 | 0 | 2 | 2 | | 2014 | 3 | 1 | 4 | | 2015 | 3 | 2 | 5 | | 2016 | 4 | 3 | 7 | | 2017 | 0 | 2 | 2 | | 2018 | 1 | 1 | 2 | | 2019 | 3 | 1 | 4 | | 2020 | 0 | 8 | 8 | | 2021 | 3 | 4 | 7 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Albuminuria" by people in Profiles.
-
Khan MS, Bakris GL, Packer M, Shahid I, Anker SD, Fonarow GC, Wanner C, Weir MR, Zannad F, Butler J. Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J. 2022 04 06; 43(14):1379-1400.
-
Chiu N, Aggarwal R, Bakris GL, Pitt B, Bhatt DL. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 04 05; 11(7):e025079.
-
Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JFE, Nauck MA, Rasmussen S, Rossing P, Wolthers B, Zinman B, Perkovic V. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585.
-
Wang AA, Cai X, Srivastava A, Prasad PV, Sprague SM, Carr J, Wolf M, Ix JH, Block GA, Chonchol M, Raphael KL, Cheung AK, Raj DS, Gassman JJ, Rahsepar AA, Middleton JP, Fried LF, Sarnari R, Isakova T, Mehta R. Abnormalities in Cardiac Structure and Function among Individuals with CKD: The COMBINE Trial. Kidney360. 2022 02 24; 3(2):258-268.
-
Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022 01; 18(1):56-70.
-
Heerspink HJL, Xie D, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Perkovic V, Rossing P, Parving HH, de Zeeuw D. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911.
-
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 12 09; 385(24):2252-2263.
-
Bakris GL, Mikami H, Hirata M, Nakajima A, Cressman MD. A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. Kidney360. 2021 08 26; 2(8):1240-1250.
-
Jardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R, Bakris GL, Cannon CP, Charytan DM, Greene T, Levin A, Li JW, Neuen BL, Neal B, Oh R, Oshima M, Pollock C, Wheeler DC, de Zeeuw D, Zhang H, Zinman B, Mahaffey KW, Perkovic V. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.
-
Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP, Chickering JG, Chien YT, Carlson K, Cressman MD, Currie MG, Milne GT, Profy AT. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|